HTA bodies

ESCAT v2 Makes Resistance Clinically Actionable
ESMO has updated its international framework for molecular actionability and introduced a parallel evidence scale for resistance biomarkers. The change reflects a simple reality: sequencing reports need to communicate not only what may work, but what the evidence says probably will not.

Divarasib Raises the KRAS G12C Bar

Precision Oncology Has a Scale Problem

Survodutide’s Phase III data raise a bigger question than weight loss

Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.

Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.

Not All Fat Is Obesity: Lipedema Trial Challenges Weight-Centred Care

The first oral PCSK9 inhibitor is approved. A pill will not fix cholesterol access by itself

Oral GLP-1 drugs could widen access, but high prices may do the opposite

Boehringer Ingelheim is adding a third target to obesity treatment.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
